Drugs & TargetsFree FDA issues alert about increased risk of death associated with Pepaxto July 30, 2021Vol.47 No.30
Drugs & Targets Keytruda + Lenvima receive FDA approval for advanced endometrial carcinoma July 23, 2021Vol.47 No.29
Drugs & Targets Rezurock receives FDA approval for chronic graft-versus-host disease July 23, 2021Vol.47 No.29
Drugs & Targets Venclexta + azacitidine receive breakthrough therapy designation from FDA for myelodysplastic syndromes July 23, 2021Vol.47 No.29
Drugs & Targets Darzalex Faspro + pomalidomide and dexamethasone receives FDA approval for multiple myeloma July 16, 2021Vol.47 No.28
Drugs & Targets Padcev receives regular approval from FDA for locally advanced or metastatic urothelial cancer July 16, 2021Vol.47 No.28
Drugs & Targets Merck will withdraw Keytruda’s “dangling” indication for gastric cancer July 09, 2021Vol.47 No.27
Drugs & Targets Rylaze receives FDA approval as component of chemotherapy regimen for leukemia and lymphoma July 02, 2021Vol.47 No.26
